文献速递间质性肺疾病

北美与大洋洲间质性肺疾病治疗的性别与种族差异

Sex- and Race-Based Differences in the Treatment of Interstitial Lung Diseases in North America and Australasia.
PubMed 文献 · Chest · 2023-01-05

该观察性研究基于三个前瞻性纵向注册队列,比较间质性肺疾病(ILD)患者中按出生性别和种族划分的治疗启动差异。加拿大队列中男性和白人患者接受治疗比例更高,芝加哥队列中女性和非白人患者比例更高,大洋洲队列无差异;白人种族在加拿大与更早启动治疗相关,在大洋洲则相反。

要点

  • ILD治疗启动存在性别和种族差异,且不同国家队列间差异方向不一致。
  • 加拿大队列男性治疗比例47%高于女性40%,白人46%高于非白人36%。
  • 芝加哥队列男性56%低于女性64%,白人56%低于非白人69%。

核心结论

  • ILD治疗启动存在性别和种族差异,且在不同国家的队列间表现不一致。

研究设计与样本

  • 观察性研究,比较来自三个前瞻性纵向注册队列的ILD患者,共纳入4572例。
  • ILD相关药物包括抗纤维化药物和免疫调节药物;种族二分为白人与非白人。
  • 从首次ILD注册访视日期至首次用药日期确定治疗启动时间。

主要发现

  • 加拿大队列男性接受治疗比例高于女性(47% vs 40%;P < .001)。
  • 加拿大队列白人接受治疗比例高于非白人(46% vs 36%;P < .001)。
  • 芝加哥队列男性接受治疗比例低于女性(56% vs 64%;P = .005)。
  • 芝加哥队列白人接受治疗比例低于非白人(56% vs 69%;P < .001)。
  • 大洋洲队列未发现按性别或种族划分的治疗比例差异。

关键数值与推荐

  • 白人种族在加拿大队列中与所有诊断组更早启动治疗显著相关,而在大洋洲队列中关联方向相反。

临床怎么用

  • 临床中应意识到ILD治疗启动可能存在性别和种族差异,注意评估治疗决策的公平性。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Biological sex, gender, and race are important considerations in patients with interstitial lung diseases (ILDs). RESEARCH QUESTION: Does a patient's sex assigned at birth, and race, influence ILD treatment initiation? STUDY DESIGN AND METHODS: Patients with ILD from three longitudinal prospective registries were compared in this observational study. ILD-related medications included antifibrotics and immunomodulating medications. Race was dichotomized as "White" vs "non-White." Time to treatment initiation was determined from the date of the initial ILD registry visit to the date of first medication initiation. Proportions of treated patients were compared between groups by χ2 test. Cox proportional analysis was used to determine how sex and race were associated with time to treatment initiation stratified by ILD diagnosis. RESULTS: A total of 4,572 patients were included across all cohorts. The proportion of men who received treatment was higher than for women in the Canadian cohort (47% vs 40%; P < .001), and the proportion of White patients who received treatment was also higher compared with non-White patients (46% vs 36%; P < .001). In contrast, the proportion of treated men in the Chicago cohort was lower compared with women (56% vs 64%; P = .005), and that of White patients was lower compared with non-White patients (56% vs 69%; P < .001). No sex- or race-based differences in proportions of patients treated were found in the Australasian cohort. White race was significantly associated with earlier treatment initiation compared with non-White race across diagnoses in the Canadian cohort, whereas the opposite association was found in the Australasian cohort. INTERPRETATION: Sex- and race-based differences exist in the initiation of ILD treatment, with variability across different cohorts in different countries. Reasons for these differences need to be further explored in future studies.

来源:Chest,查看原文。版权归原作者所有。

引用

  1. Assayag D, Adegunsoye A, Sheehy R, et al. Sex- and Race-Based Differences in the Treatment of Interstitial Lung Diseases in North America and Australasia. Chest. 2023. PMID: 36621759. doi:10.1016/j.chest.2022.12.039

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。